ArticleEClinicalMedicine2021
A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures.
Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- Dynamic properties of Kermack-McKendrick-like models.PloS one · 2026Article
- Learning from the COVID-19 pandemic: A systematic review of mathematical vaccine prioritization models.Infectious Disease Modelling · 2024Review
- A vaccination-based COVID-19 model: Analysis and prediction using Hamiltonian Monte Carlo.Heliyon · 2024Article
- Expanding the use of mathematical modeling in healthcare epidemiology and infection prevention and control.Infection control and hospital epidemiology · 2024Review
- Learning from the COVID-19 pandemic: a systematic review of mathematical vaccine prioritization models.medRxiv : the preprint server for health sciences · 2024Article
- COVID-19 vaccination strategies in settings with limited rollout capacity: a mathematical modelling case study in Sierra Leone.BMC public health · 2023Article
- Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study.BMC medicine · 2023Article
- Article
- Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna.The Lancet regional health. Western Pacific · 2023Article
- Determinants of COVID-19 Vaccination Intention among Health Care Workers in France: A Qualitative Study.Vaccines · 2022Article
- Non-pharmaceutical interventions and their relevance in the COVID-19 vaccine rollout in Saudi Arabia and Arab Gulf countries.Infectious Disease Modelling · 2022Article
- Covid-19, an unfinished story.Presse medicale (Paris, France : 1983) · 2022Article
- Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.Vaccine · 2022Article
- Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic.BMC medicine · 2022Article
- Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges.Pharmaceutics · 2022Review
- Epidemic models: why and how to use them.Anaesthesia, critical care & pain medicine · 2022Article
- Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study.Vaccines · 2022Article
- Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19.Nature communications · 2022Article
- Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France.BMC medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe roll-out of COVID-19 vaccines is a multi-faceted challenge whose performance depends on pace of vaccination, vaccine characteristics and heterogeneities in individual risks.
methodsWe developed a mathematical model accounting for the risk of severe disease by age and comorbidity, and transmission dynamics. We compared vaccine prioritisation strategies in the early roll-out stage and quantified the extent to which measures could be relaxed as a function of the vaccine coverage achieved in France.
findingsPrioritizing at-risk individuals reduces morbi-mortality the most if vaccines only reduce severity, but is of less importance if vaccines also substantially reduce infectivity or susceptibility. Age is the most important factor to consider for prioritization; additionally accounting for comorbidities increases the performance of the campaign in a context of scarce resources. Vaccinating 90% of ≥65 y.o. and 70% of 18-64 y.o. before autumn 2021 with a vaccine that reduces severity by 90% and susceptibility by 80%, we find that control measures reducing transmission rates by 15-27% should be maintained to remain below 1000 daily hospital admissions in France with a highly transmissible variant (basic reproduction number
interpretationAge and comorbidity-based vaccine prioritization strategies could reduce the burden of the disease. Very high vaccination coverage may be required to completely relax control measures. Vaccination of children, if possible, could lower coverage targets necessary to achieve this objective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.